Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MEDP 
Medpace Holdings Inc (MEDP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: MEDP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $300.3
Year Target Price $300.3
| 2 | Strong Buy |
| 0 | Buy |
| 10 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 40.12% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.93B USD | Price to earnings Ratio 23.7 | 1Y Target Price 300.28 |
Price to earnings Ratio 23.7 | 1Y Target Price 300.28 | ||
Volume (30-day avg) - | Beta 1.48 | 52 Weeks Range 250.05 - 459.77 | Updated Date 06/29/2025 |
52 Weeks Range 250.05 - 459.77 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 13.11 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 19.31% | Operating Margin (TTM) 20.32% |
Management Effectiveness
Return on Assets (TTM) 15.45% | Return on Equity (TTM) 65.83% |
Valuation
Trailing PE 23.7 | Forward PE 25.25 | Enterprise Value 8616678996 | Price to Sales(TTM) 4.14 |
Enterprise Value 8616678996 | Price to Sales(TTM) 4.14 | ||
Enterprise Value to Revenue 4 | Enterprise Value to EBITDA 17.75 | Shares Outstanding 28741600 | Shares Floating 22544631 |
Shares Outstanding 28741600 | Shares Floating 22544631 | ||
Percent Insiders 20.55 | Percent Institutions 92.29 |
Analyst Ratings
Rating 3.33 | Target Price 300.3 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 10 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Medpace Holdings Inc
Company Overview
History and Background
Medpace Holdings Inc was founded in 1992. It has grown from a small research organization to a global full-service clinical contract research organization (CRO). Medpace's focus has always been on scientifically-driven clinical development.
Core Business Areas
- Clinical Development Services: Medpace provides a full suite of clinical development services, including clinical trial management, data management, biostatistics, medical writing, regulatory affairs, and clinical monitoring.
- Central Laboratory Services: Medpace operates a central laboratory that provides a full range of laboratory testing services for clinical trials.
- Medical Device Development: Medpace supports medical device companies with clinical trial strategy, execution, and regulatory submissions.
Leadership and Structure
August J. Troendle, M.D. is the CEO and co-founder of Medpace. The organizational structure is designed to support a decentralized and therapeutically-focused approach, with experienced medical and scientific leadership at the core.
Top Products and Market Share
Key Offerings
- Clinical Trial Management: Medpace's comprehensive clinical trial management service is their core offering. They manage all phases of clinical trials. Market share data specific to clinical trial management is fragmented across therapeutic areas but Medpace is a mid-sized player, with growth surpassing larger players. Competitors include IQVIA (IQV), Labcorp (LH), and PPD (now part of Thermo Fisher Scientific (TMO)).
- Laboratory Services: Their central laboratory supports clinical trials with a full range of testing. This is essential to any CRO. Exact revenue attributable to this service is not publicly disclosed. Competitors include Labcorp (LH) and Quest Diagnostics (DGX), as well as smaller niche labs.
Market Dynamics
Industry Overview
The CRO industry is experiencing steady growth, driven by increasing R&D spending in the pharmaceutical and biotechnology sectors, and the growing complexity of clinical trials.
Positioning
Medpace is positioned as a scientifically-driven, full-service CRO focused on complex trials and niche therapeutic areas. Their competitive advantage lies in their therapeutic expertise, experienced staff, and decentralized model.
Total Addressable Market (TAM)
The global CRO market is estimated to be over $70 billion, with projections of continuous growth. Medpace is well-positioned to capture a significant share of this expanding market, focusing on complex and specialized clinical trials.
Upturn SWOT Analysis
Strengths
- Therapeutic Expertise
- Strong Management Team
- Decentralized Model
- High-Growth Rate
- Focus on complex clinical trials
Weaknesses
- Smaller Size Compared to Larger CROs
- Dependence on Key Personnel
- Potential impact of economic downturn
Opportunities
- Expansion into New Geographic Markets
- Increased Outsourcing of Clinical Trials
- Growth in Biopharmaceutical R&D
- Strategic Acquisitions
Threats
- Increased Competition
- Regulatory Changes
- Economic Downturn
- Consolidation in the Pharmaceutical Industry
Competitors and Market Share
Key Competitors
- IQV
- LH
- TMO
Competitive Landscape
Medpace competes with larger, more established CROs but differentiates itself through its therapeutic expertise, decentralized model, and focus on scientifically-driven clinical development. Medpace's smaller size compared to larger competitors allows for more agile project management.
Major Acquisitions
Synchrogenix Information Strategies, LLC
- Year: 2017
- Acquisition Price (USD millions): 46
- Strategic Rationale: Enhanced medical writing capabilities and expanded regulatory affairs expertise.
Growth Trajectory and Initiatives
Historical Growth: Medpace has experienced significant revenue and earnings growth over the past several years.
Future Projections: Analysts project continued revenue and earnings growth for Medpace, driven by the increasing demand for clinical trial services.
Recent Initiatives: Medpace has focused on expanding its geographic reach and strengthening its therapeutic expertise through strategic hires and investments.
Summary
Medpace is a strong, growing company in the CRO industry, driven by its scientific expertise and efficient operational model. Its focus on complex trials and niche therapeutic areas provides a competitive edge. The company must remain agile to compete with bigger competitors and be aware of regulatory and economic conditions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q), Company Investor Relations, Analyst Reports, Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated based on available sources and may not be precise. Financial data is based on past performance and is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Medpace Holdings Inc
Exchange NASDAQ | Headquaters Cincinnati, OH, United States | ||
IPO Launch date 2016-08-11 | Chairman & CEO Dr. August James Troendle M.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 5900 | Website https://www.medpace.com |
Full time employees 5900 | Website https://www.medpace.com | ||
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.